<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Razi Journal of Medical Sciences</title>
<title_fa>مجله علوم پزشکی رازی</title_fa>
<short_title>RJMS</short_title>
<subject>Medical Sciences</subject>
<web_url>http://rjms.iums.ac.ir</web_url>
<journal_hbi_system_id>39</journal_hbi_system_id>
<journal_hbi_system_user>journal39</journal_hbi_system_user>
<journal_id_issn>2228-7043</journal_id_issn>
<journal_id_issn_online>2228-7051</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi></journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1400</year>
	<month>12</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2022</year>
	<month>3</month>
	<day>1</day>
</pubdate>
<volume>29</volume>
<number>1</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>fa</language>
	<article_id_doi></article_id_doi>
	<title_fa>بهینه‌سازی مدل فازی مسئله براکی تراپی با میزان دوز بالا برای درمان سرطان پروستات با استفاده از الگوریتم‌های تکاملی</title_fa>
	<title>Optimization of Fuzzy Model of High Dose Brachytherapy Problem for the Treatment of Prostate Cancer Using Evolutionary Algorithms</title>
	<subject_fa>فیزیک‌پزشکی</subject_fa>
	<subject>Biophysics</subject>
	<content_type_fa>پژوهشي</content_type_fa>
	<content_type>Research</content_type>
	<abstract_fa>&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;text-justify:kashida&quot;&gt;&lt;span style=&quot;text-kashida:0%&quot;&gt;&lt;span style=&quot;tab-stops:10.5pt&quot;&gt;&lt;span style=&quot;direction:rtl&quot;&gt;&lt;span style=&quot;unicode-bidi:embed&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:Calibri,&amp;quot;sans-serif&amp;quot;&quot;&gt;&lt;span dir=&quot;LTR&quot; style=&quot;font-size:10.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;text-justify:kashida&quot;&gt;&lt;span style=&quot;text-kashida:0%&quot;&gt;&lt;span style=&quot;tab-stops:10.5pt&quot;&gt;&lt;span style=&quot;direction:rtl&quot;&gt;&lt;span style=&quot;unicode-bidi:embed&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:Calibri,&amp;quot;sans-serif&amp;quot;&quot;&gt;&lt;b&gt;&lt;span lang=&quot;FA&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;B Mitra&amp;quot;&quot;&gt;&lt;span style=&quot;color:#0070c0&quot;&gt;زمینه و هدف: &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;span lang=&quot;AR-SA&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;B Mitra&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;سرطان پروستات یکی از شایع&#8204;ترین سرطان در مردان است. یکی&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;b&gt; &lt;/b&gt;&lt;span lang=&quot;AR-SA&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;B Mitra&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;از&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;b&gt; &lt;/b&gt;&lt;span lang=&quot;AR-SA&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;B Mitra&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;روش&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;b&gt;&lt;span dir=&quot;LTR&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&#8204;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;span lang=&quot;AR-SA&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;B Mitra&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;ها درمانی سرطان پروستات که دارای نتایج بهتری نسبت به دیگر روش&#8204;های متداول هست، روش براکی تراپی است. مسئله &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;FA&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;B Mitra&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;برنامه&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;b&gt;&lt;span dir=&quot;LTR&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&#8204;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;span lang=&quot;FA&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;B Mitra&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;ریزی درمان براکی تراپی با نرخ دوز بالا،&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;b&gt; &lt;/b&gt;&lt;span lang=&quot;FA&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;B Mitra&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;شامل تعیین یک برنامه مناسب برای یک منبع تشعشع است که در بدن بیمار حرکت می&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;b&gt;&lt;span dir=&quot;LTR&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&#8204;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;span lang=&quot;FA&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;B Mitra&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;کند و حجم هدف با دوز برنامه&#8204;ریزی شده، اشعه&#8204;دهی می&#8204;شود.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;text-justify:kashida&quot;&gt;&lt;span style=&quot;text-kashida:0%&quot;&gt;&lt;span style=&quot;tab-stops:10.5pt&quot;&gt;&lt;span style=&quot;direction:rtl&quot;&gt;&lt;span style=&quot;unicode-bidi:embed&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:Calibri,&amp;quot;sans-serif&amp;quot;&quot;&gt;&lt;b&gt;&lt;span lang=&quot;FA&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;B Mitra&amp;quot;&quot;&gt;&lt;span style=&quot;color:#0070c0&quot;&gt;روش کار:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;span lang=&quot;FA&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;B Mitra&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt; در این مقاله، برنامه&#8204;ریزی اعداد صحیح با محدودیت&#8204;های فازی توسعه داده شده و یک مدل بهینه&#8204;سازی برای محاسبه میزان دوز در روش براکی تراپی، برنامه&#8204;ریزی شده است. سپس توسط سه نوع الگوریتم تکاملی مختلف، جواب های بهینه مسئله برنامه&#8204;ریزی اعداد صحیح با محدودیت&#8204;های فازی بدست آورده و با هم مقایسه شده است.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;text-justify:kashida&quot;&gt;&lt;span style=&quot;text-kashida:0%&quot;&gt;&lt;span style=&quot;tab-stops:10.5pt&quot;&gt;&lt;span style=&quot;direction:rtl&quot;&gt;&lt;span style=&quot;unicode-bidi:embed&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:Calibri,&amp;quot;sans-serif&amp;quot;&quot;&gt;&lt;b&gt;&lt;span lang=&quot;FA&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;B Mitra&amp;quot;&quot;&gt;&lt;span style=&quot;color:#0070c0&quot;&gt;یافته&#8204;ها:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;span lang=&quot;FA&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;B Mitra&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt; با توجه به نتایج بدست آمده و مقایسه الگوریتم&#8204;های مختلف، می&#8204;توان نتیجه گرفت که چه در حالتی که هدف اصلی، بیشترین پوشش باشد و یا هدف، کمترین زمان ممکن برای رسیدن به پوشش بالای 95 درصد باشد، بهترین الگوریتمی که می&#8204;تواند جواب خوبی برای هر بیمار بدست آید، الگوریتم استراتژی تکاملی می&#8204;باشد. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;text-justify:kashida&quot;&gt;&lt;span style=&quot;text-kashida:0%&quot;&gt;&lt;span style=&quot;tab-stops:10.5pt&quot;&gt;&lt;span style=&quot;direction:rtl&quot;&gt;&lt;span style=&quot;unicode-bidi:embed&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:Calibri,&amp;quot;sans-serif&amp;quot;&quot;&gt;&lt;b&gt;&lt;span lang=&quot;FA&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;B Mitra&amp;quot;&quot;&gt;&lt;span style=&quot;color:#0070c0&quot;&gt;نتیجه&#8204;گیری:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;span lang=&quot;FA&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;B Mitra&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt; در این پژوهش نشان داده شده است که این مدل فازی دارای عملکرد قابل قبول بالینی برای موارد پروستات و معیارهای دزیمتری مورد استفاده در این مطالعه می&#8204;باشد. از طرفی چون سن بیمار و وضعیت و توانایی جسمانی بیمار به عنوان پارامترهایی در مسئله تاثیر گذار می باشند، لذا جواب&#8204;هایی که بدست آمده، جواب&#8204;های بهتر و دقیق&#8204;تری نسبت به تحقیقات گذشته می&#8204;باشد. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;text-justify:kashida&quot;&gt;&lt;span style=&quot;text-kashida:0%&quot;&gt;&lt;span style=&quot;tab-stops:10.5pt&quot;&gt;&lt;span style=&quot;direction:rtl&quot;&gt;&lt;span style=&quot;unicode-bidi:embed&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:Calibri,&amp;quot;sans-serif&amp;quot;&quot;&gt;&lt;span lang=&quot;FA&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;B Mitra&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</abstract_fa>
	<abstract>&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;text-justify:kashida&quot;&gt;&lt;span style=&quot;text-kashida:0%&quot;&gt;&lt;span style=&quot;tab-stops:10.5pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:Calibri,&amp;quot;sans-serif&amp;quot;&quot;&gt;&lt;b&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;&quot;&gt;&lt;span style=&quot;color:#0070c0&quot;&gt;Background &amp; Aims:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt; &lt;span style=&quot;font-size:10.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;Cancer is one of the great human challenges in all countries, both advanced and developing. Cancer treatment management can include surgery, chemotherapy, or radiation therapy (1). Radiation therapy is done in two ways: Teletherapy and Brachytherapy. Brachytherapy involves the use of radiation sources to treat cancer by irradiating cancerous tissue from within the patient&amp;rsquo;s body (2). But the dose and how to use this method has always been questionable for researchers. Therefore, this study creates a new fuzzy approach to high-dose brachytherapy by optimizing the distribution of double roughness based on dosimetric criteria. The use of fuzzy logic itself has increased the accuracy of the mathematical model of the problem. This fuzzy model is a new study and innovation used in this paper. Due to the fuzzy nature of this method and its limitations, it is considered fuzzy. This makes the method more accurate and includes parameters such as the patient&amp;rsquo;s physical ability and age in the problem, which in itself increases the accuracy of the method for each patient. As a result, the obtained answer is improved and the executive program of brachytherapy method is more accurate.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;text-justify:kashida&quot;&gt;&lt;span style=&quot;text-kashida:0%&quot;&gt;&lt;span style=&quot;tab-stops:10.5pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:Calibri,&amp;quot;sans-serif&amp;quot;&quot;&gt;&lt;b&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;&quot;&gt;&lt;span style=&quot;color:#0070c0&quot;&gt;Methods:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt; In the present study, the dose prescribed for an organ was evaluated by dosimetric indices listed in Table 1 (18). For the present study, data from 20 patients in the age range of 50 to 74 and mean age 62 years with a wide range of prostate volume between 23 and 103 cubic centimeters, and for the treatment of prostate cancer by brachytherapy from the Academic Medical Center (AMC, Amsterdam, the Netherlands) had participated. To compare brachytherapy programs with high interstitial dose, the dose rate was calculated with 192Ir beam with a radiation dose of 13 Gy, according to the standard protocol TG-43.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;text-justify:kashida&quot;&gt;&lt;span style=&quot;text-kashida:0%&quot;&gt;&lt;span style=&quot;tab-stops:10.5pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:Calibri,&amp;quot;sans-serif&amp;quot;&quot;&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;To begin with, computed tomography (CT) scans or magnetic resonance imaging (MRI) were taken from the patients pelvis, and entered into the treatment planning software for use in treatment planning sessions. BT treatment planners and specialists then determined the input catheters, target volumes, and OARs obtained from the medical images. Depending on the size and exact location of the target volumes, between 14 and 20 catheters entered the patient&amp;rsquo;s body, reaching the target volumes. After designing and approving an acceptable treatment plan, the catheters inserted into the patient&amp;rsquo;s body were connected to a retractor 4 that controls the movement of the radiation source. After the treatment program, the source was returned to the retractor (8, 14).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;text-justify:kashida&quot;&gt;&lt;span style=&quot;text-kashida:0%&quot;&gt;&lt;span style=&quot;tab-stops:10.5pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:Calibri,&amp;quot;sans-serif&amp;quot;&quot;&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;Then, an integer program model with fuzzy constraints was proposed for programming on high-dose brachytherapy. The description of infrastructures, parameters and variables in this model are in Table 2 (15). Finally, the dosimeter index is equal to the sum of all the index variables, as it turned out: The proposed model is a correct programming model called IP.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;text-justify:kashida&quot;&gt;&lt;span style=&quot;text-kashida:0%&quot;&gt;&lt;span style=&quot;tab-stops:10.5pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:Calibri,&amp;quot;sans-serif&amp;quot;&quot;&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;In general, three evolutionary algorithms (EP), (GA) and (ES) were used in this research. The algorithms stopped after creating 20 generations of desirable answers and the best answer of each generation was determined on the chart as a point. The resulting set of answers were connected in the form of graphs, which are used to analyze the results. Each point on the graph identifies the best answer from each of the generations generated by the respective algorithms. These three algorithms were performed independently for each patient and the obtained answers were identified as dots on the chart. The graph obtained for each patient indicates the capability of each of these algorithms.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;text-justify:kashida&quot;&gt;&lt;span style=&quot;text-kashida:0%&quot;&gt;&lt;span style=&quot;tab-stops:10.5pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:Calibri,&amp;quot;sans-serif&amp;quot;&quot;&gt;&lt;b&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;&quot;&gt;&lt;span style=&quot;color:#0070c0&quot;&gt;Results:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt; According to this study, each of the three algorithms (EP), (GA) and (ES) are each run independently for each of the patients with prostate cancer. At first, the genetic algorithm showed the ability to get closer to the desired answer sooner, but as the optimization process continues, the rate of convergence to the desired answer decreases, so if the time parameter is very important, the genetic algorithm can be useful. Especially for patients whose prostate volume was larger than other patients. In patients 15, 12, 8 and 9, due to their younger age than other patients and better physical condition, as well as prostate volume less than 80 ml, they had much more promising results than other patients. In contrast, for patients 4 and 19 with an age of over 70, the results were not as favorable as for other patients. The * sign in the table indicates that there is no answer through that patient-specific algorithm that covers 95 or even more of the tumor volume. Therefore, according to Table 2, it can be concluded that the best algorithm that can be considered for the case where the shortest time to reach the target coverage above 95% is the genetic algorithm.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;text-justify:kashida&quot;&gt;&lt;span style=&quot;text-kashida:0%&quot;&gt;&lt;span style=&quot;tab-stops:10.5pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:Calibri,&amp;quot;sans-serif&amp;quot;&quot;&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;According to Table 2, it can be concluded that the best algorithm that can be considered for the case where the shortest time to reach the target coverage above 95% is the genetic algorithm.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;text-justify:kashida&quot;&gt;&lt;span style=&quot;text-kashida:0%&quot;&gt;&lt;span style=&quot;tab-stops:10.5pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:Calibri,&amp;quot;sans-serif&amp;quot;&quot;&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;Therefore, according to Table 3, the ES algorithm has better answers than the other two algorithms for the case in which the largest volume of the tumor is covered. According to the results, the ES algorithm has obtained the best results for patients under 60 years of age and normal prostate volume.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;text-justify:kashida&quot;&gt;&lt;span style=&quot;text-kashida:0%&quot;&gt;&lt;span style=&quot;tab-stops:10.5pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:Calibri,&amp;quot;sans-serif&amp;quot;&quot;&gt;&lt;b&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;&quot;&gt;&lt;span style=&quot;color:#0070c0&quot;&gt;Conclusion:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt; &lt;span style=&quot;font-size:10.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;According to the obtained results, it can be stated that whether the main goal is the maximum coverage or the goal is the shortest possible time to reach the coverage above 95%, the best algorithm that can get a good answer for each patient is the evolutionary strategy algorithm. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;text-justify:kashida&quot;&gt;&lt;span style=&quot;text-kashida:0%&quot;&gt;&lt;span style=&quot;tab-stops:10.5pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:Calibri,&amp;quot;sans-serif&amp;quot;&quot;&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</abstract>
	<keyword_fa>بهینه سازی, براکی تراپی,  منطق فازی, الگوریتم های تکاملی</keyword_fa>
	<keyword>Optimization, Brachytherapy, Fuzzy Logic, Evolutionary Algorithms</keyword>
	<start_page>84</start_page>
	<end_page>95</end_page>
	<web_url>http://rjms.iums.ac.ir/browse.php?a_code=A-10-5746-1&amp;slc_lang=fa&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Mohammad</first_name>
	<middle_name></middle_name>
	<last_name>Mohammadi Najafabadi</last_name>
	<suffix></suffix>
	<first_name_fa>محمد</first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa>محمدی نجف آبادی</last_name_fa>
	<suffix_fa></suffix_fa>
	<email>mm.najafabadi@pun.ac.ir</email>
	<code>3900319475328460064360</code>
	<orcid>3900319475328460064360</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>PhD Student, Department of Mathematics, Payame Noor University, Tehran, Iran</affiliation>
	<affiliation_fa>دانشجوی دکتری، گروه ریاضی، دانشگاه پیام نور، تهران، ایران</affiliation_fa>
	 </author>


	<author>
	<first_name>Habibeh</first_name>
	<middle_name></middle_name>
	<last_name>Nazif</last_name>
	<suffix></suffix>
	<first_name_fa>حبیبه</first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa>نظیف</last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>3900319475328460064361</code>
	<orcid>3900319475328460064361</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Associate Professor, Department of Mathematics, Payame Noor University, Tehran, Iran</affiliation>
	<affiliation_fa>دانشیار، گروه ریاضی، دانشگاه پیام نور، تهران، ایران</affiliation_fa>
	 </author>


	<author>
	<first_name>Fahimeh</first_name>
	<middle_name></middle_name>
	<last_name>soltanian</last_name>
	<suffix></suffix>
	<first_name_fa>فهیمه</first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa>سلطانیان</last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>3900319475328460064362</code>
	<orcid>3900319475328460064362</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Assistant Professor, Department of Mathematics, Payame Noor University, Tehran, Iran</affiliation>
	<affiliation_fa>استادیار، گروه ریاضی، دانشگاه پیام نور، تهران، ایران</affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
